SeaStar's QUELIMMUNE Cuts Pediatric Sepsis Deaths by Half
SeaStar Medical's QUELIMMUNE device reduces pediatric sepsis deaths by 50%, offering new hope for treating acute kidney injury in critically ill children.
This news matters because it highlights a groundbreaking medical advancement that significantly reduces mortality rates in pediatric patients suffering from acute kidney injury due to sepsis. The QUELIMMUNE device offers a new hope for families and healthcare providers by providing an effective treatment that can save lives and improve recovery outcomes, potentially setting a new standard in critical care for children.
